Drug intelligence / Profile preview

faropenem + clavulanate

Development stage
Unknown
Lead developer
Suntory
Modality
Small Molecules
Administration
Oral
01

Overview

Faropenem + clavulanate (also known as faropenem/clavulanate) is an oral antibacterial combination drug that pairs faropenem, a penem-class beta-lactam antibiotic, with clavulanate (clavulanic acid), a beta-lactamase inhibitor. Faropenem works by binding to penicillin-binding proteins (PBPs) to inhibit bacterial cell wall synthesis, leading to cell lysis and death. Clavulanate acts as a suicide inhibitor of beta-lactamase enzymes, preventing them from degrading faropenem and thereby restoring and extending its antibacterial spectrum against resistant, beta-lactamase-producing pathogens. This combination is approved and marketed in India for treating various moderate-to-severe bacterial infections, including respiratory tract infections (such as pneumonia, bronchitis, and sinusitis), urinary tract infections, skin and soft tissue infections, gynecological infections, and dental infections.

Brand names
Depenem CVFaroPair CVFaroalfa CVFarochem-CV 325Farochem-CV325Farochem-CV-325FARODEN-CVFarofence CVFaroline-CVFaromik CVFAROMITS CVFaronem CVFAROPINOM DUOFaropare cvFarovil CVFazrix CVFcvergeFerocan-CVFerofic CVForth CVINTRAPAM-CVPlerocin CV
Other names
faropenem + clavulanic acidfaropenem and clavulanatefaropenem and clavulanic acidfaropenem sodium + potassium clavulanatefaropenem sodium and potassium clavulanatefaropenem/clavulanatefaropenem/clavulanic acid
02

Targets

β-lactamaseNeuraminidasePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on faropenem + clavulanate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on faropenem + clavulanate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call